cropped-logo.png

RegenSight

We are the TECH Company

  • Company
      • About Us
      • Team
      • Resources & Opportunities
  • Science & Technology
      • Technologies
      • Projects
      • Clinical Trials
      • Visual Disorder
      • Publications and Presentations
  • Products
      • Devices for the CXL
        • C4V CHROMO4VIS
        • RitSight
      • Medical Professionals
      • Partnership
  • Granting & Investing
      • Public Granting
      • Investing
  • News & Media
  • Contacts
  • English
    • Italiano

Home

Monthly Archives: July 2024

ARGO clinical study published in Ophthalmology
July 21, 2024
by Marco Lombardo News

ARGO clinical study published in the prestigious scientific journal Ophthalmology

🔬 Breakthrough Advancement in Clinical Research for the Treatment of Keratoconus 🔬 We are excited to announce the publication of the ARGO clinical trial validating theranostics technology  for the precision, predictive and personalized treatment of ke ...

Leggi di più

Search

Recent Posts

  • Il progetto Teracor per la correzione dei disturbi visivi con la teranostica avanza rapidamente
  • ARGO clinical study published in the prestigious scientific journal Ophthalmology
  • Regensight at ESCRS 2024
  • New Publication on Regensight: A Clear Future for Young People with Keratoconus
  • RitSight is the riboflavin ophthalmic solution with highest performance for corneal cross-linking

Recent Comments

    Archives

    • September 2024
    • July 2024
    • June 2024
    • April 2024
    • February 2024
    • November 2023
    • September 2023
    • August 2023
    • June 2023
    • May 2023
    • April 2023
    • January 2023
    • December 2022
    • October 2022
    • September 2022
    • August 2022
    • June 2022
    • January 2022
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • July 2021

    Categories

    • BUSINESS
    • News
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Premio di Ricerca

    Mario Lombardo

    Ad un giovane ricercatore impegnato nello studio del cheratocono

    Scopri di più
    cropped-logo.png

    The TECH Company

    Regensight è l’azienda biomedicale che ha sviluppato la teranostica per offrire trattamenti oftalmici personalizzati e migliorare la vista e la qualità della vita a chi soffre di disturbi visivi ad ogni età.

    Info
    Regensight srl è azienda certificata ISO 13485:2021. Organismo Notificato: TÜV Rheinland Italia.

    Informativa ai sensi dell’art. 13 del Regolamento UE 2016/679

    Links Utili
    • Home
    • Products
    • Contacts
    • News & Media
    • Privacy Policy
    • Cookies Policy
    Nota

    Le informazioni del «Sito» relative a dispositivi medici non sono di natura pubblicitaria ma materiale informativo rivolto esclusivamente al personale medico. Proseguendo nella navigazione l’utente dichiara di essere un Professionista dell’area sanitaria

    Sign Up

    Keep me up to date with content, updates, and offers from Phlox

    "MailChimp" Plugin is Not Activated! In order to use this element, you need to install and activate this plugin.
    © 2024. Regensight | Creative web design by Arkomedia Web Agency
    Shopping Basket
    Utilizziamo i cookie per personalizzare i contenuti e per analizzare il traffico sul nostro sito. Accetta o rifiuta i cookies se continui ad utilizzare il nostro sito web.
    PersonalizzaAccetto Rifiuto Cookies policy
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    SAVE & ACCEPT